VIRX Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (25 Apr 2024 @ 16:00):

Stats
Today's Volume	37 784.00
Average Volume	114 674
Market Cap	33.26M
EPS	$0 ( 2024-03-11 )
Next earnings date	( $-0.350 ) 2024-05-13
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.640
ATR14	$0.00600 (0.72%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-20	Burcar Melody	Sell	80 000	Stock Option (Right to Buy)
2024-03-20	Burcar Melody	Sell	47 500	Stock Option (Right to Buy)
2024-03-20	Burcar Melody	Sell	33 250	Stock Option (Right to Buy)
2024-03-20	Burcar Melody	Sell	100 000	Stock Option (Right to Buy)
2024-03-12	Rothera Mark	Buy	475 000	Stock Option (Right to Buy)

INSIDER POWER
67.86
Last 97 transactions
Buy: 4 797 715 \| Sell: 606 024

Volume Correlation

Long: 0.15 (neutral)

Short: 0.89 (strong)

Signal:(48.987) Same movement expected

Sunesis Pharmaceuticals Correlation

10 Most Positive Correlations
TOI	0.962
WISA	0.959
TIL	0.958
ONCS	0.958
VSTA	0.948
IMRX	0.943
TFFP	0.94
MTSL	0.934
NOTV	0.93
HCDIP	0.929

10 Most Negative Correlations
AMRB	-0.931
MNKD	-0.915
CCRC	-0.915
IBEX	-0.907
SRAC	-0.904
PBFS	-0.903
RAVN	-0.901
SLGN	-0.898
SEDG	-0.896
MGI	-0.896

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Sunesis Pharmaceuticals Correlation - Currency/Commodity

0.14
( neutral )

0.29
( neutral )

0.00
( neutral )

0.39
( neutral )

Sunesis Pharmaceuticals Financials

Annual	2023
Revenue:	$0
Gross Profit:	$-492 000 (0.00 %)
EPS:	$-1.320

Q4	2023
Revenue:	$0
Gross Profit:	$-123 000 (0.00 %)
EPS:	$-0.350

Q3	2023
Revenue:	$0
Gross Profit:	$-128 000 (0.00 %)
EPS:	$-0.330

Q2	2023
Revenue:	$0
Gross Profit:	$-119 000 (0.00 %)
EPS:	$-0.320

Financial Reports:

No articles found.

Sunesis Pharmaceuticals

Viracta Therapeutics, Inc., a precision oncology company, engages in developing drugs for the treatment of virus-associated malignancies. Its lead product candidature includes Nana-val, in combination with nanatinostat and valganciclovir that is in Phase II clinical trial for Epstein-Barr virus-positive lymphoma; and open-label Phase 2 basket trial for the treatment of various relapsed/refractory Epstein-Barr virus-positive (EBV+) lymphoma, as well as an open-label Phase 1b/2 trial for the treatment of EBV+ recurrent or metastatic nasopharyngeal carcinoma and other EBV+ solid tumors. The company's development pipeline includes vecabrutinib, a clinical-stage non-covalent ITK/BTK inhibitor and VRx-510 (formerly SNS-510), a preclinical-stage PDK-1 inhibitor. It is evaluating development and collaboration opportunities for vecabrutinib in combination with chimeric antigen receptor T-cell therapies and VRx-510 in various oncology indications. The company was formerly known as Sunesis Pharmaceuticals, Inc. to Viracta Therapeutics, Inc. in February 25, 2021. Viracta Therapeutics, Inc. was incorporated in 1998 and is headquartered in Cardiff-by-the-Sea, California.